News

Public · Published

Contineum Therapeutics, Inc. expected to post a loss of 45 cents a share - Earnings Preview

Contineum Therapeutics is expected to report no change in quarterly revenue for the period ending September 30, 2026. Analysts expect a loss of 45 cents a share, and the average rating is buy with a $22.00 median price target.

Published:

Updated:

What happened

Contineum Therapeutics is expected to report no change in quarterly revenue for the period ending September 30, 2026. Analysts expect a loss of 45 cents a share, and the average rating is buy with a $22.00 median price target.

Confirmed

Global impact / market context

A expected loss of 45 cents a share means the company is likely spending more than it earns, which can reduce cash available over time. The buy rating and $22.00 price target suggest analysts see recovery potential despite losses.

Analyst inference

The median price target of $22.00 is about 164.7% above the last closing price of $8.31, meaning analysts see large potential upside. Past results show mixed beats and misses, so investors may expect volatility around earnings.

Analyst inference

What to watch

  1. Watch whether revenue shows no change versus the prior-year quarter, as the estimate suggests, and whether the loss matches the expected 45 cents a share. Confirmed
  2. Watch for any change in the mix of analyst ratings, since six buyers and two holders currently shape expectations for the stock's direction. Analyst inference
  3. Watch how the company manages spending and cash use, since repeated losses can influence future capital spending and the ability to fund operations. Proposed

Evidence

  • Original source link unavailable